Personalis Current Ratio 2018-2024 | PSNL

Personalis current ratio from 2018 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Personalis Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2024-09-30 $0.17B $0.04B 4.68
2024-06-30 $0.11B $0.03B 3.31
2024-03-31 $0.12B $0.03B 3.84
2023-12-31 $0.15B $0.05B 3.11
2023-09-30 $0.15B $0.03B 4.56
2023-06-30 $0.16B $0.03B 5.63
2023-03-31 $0.18B $0.03B 5.35
2022-12-31 $0.20B $0.03B 6.03
2022-09-30 $0.22B $0.03B 6.58
2022-06-30 $0.26B $0.04B 6.27
2022-03-31 $0.29B $0.04B 7.38
2021-12-31 $0.32B $0.03B 10.16
2021-09-30 $0.33B $0.03B 12.41
2021-06-30 $0.35B $0.03B 10.39
2021-03-31 $0.37B $0.04B 9.66
2020-12-31 $0.22B $0.04B 5.43
2020-09-30 $0.22B $0.04B 6.23
2020-06-30 $0.12B $0.04B 2.79
2020-03-31 $0.14B $0.05B 2.60
2019-12-31 $0.14B $0.05B 2.79
2019-09-30 $0.14B $0.05B 2.96
2019-06-30 $0.18B $0.06B 3.13
2019-03-31 $0.00B 0.00
2018-12-31 $0.00B 0.00
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
2017-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.412B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.441B 7.12
Dr Reddy's Laboratories (RDY) India $11.160B 21.29
BridgeBio Pharma (BBIO) United States $6.858B 0.00
Bausch Health Cos (BHC) Canada $2.354B 1.71
Supernus Pharmaceuticals (SUPN) United States $1.851B 25.20
Amphastar Pharmaceuticals (AMPH) United States $1.501B 9.02
Taysha Gene Therapies (TSHA) United States $0.336B 23.43
Assembly Biosciences (ASMB) United States $0.081B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.008B 0.00
Teligent (TLGT) United States $0.000B 0.00